2 unknown, 1 completed. 2 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Phase 4 | 1 | Unknown 1 |
Follow ALK-negative Anaplastic Large Cell Lymphoma: new trials by email Literature Review of ALK-negative Anaplastic Large Cell Lymphoma trials Research Report on ALK-negative Anaplastic Large Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Tislelizumab - Peripheral T Cell Lymphoma, PTCL | Phase 2 | Completed | BeiGene | 77 | 2018-04-13 | 2024-10-26 |
| CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL CEOP/IVE/GDP chemotherapy regimen, CEOP chemotherapy regimen for 6 cycles - Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma | Phase 2 | Unknown | Shandong Provincial Hospital | 106 | 2015-09-01 | 2020-03-10 |
| CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Cyclophosphamide 750mg/m2, Vincristine 1.4mg/m2, Doxorubicin 50mg/m2 - ALK-negative Anaplastic Large Cell Lymphoma, Peripherial T Cell Lymphoma,Not Otherwise Specified | Phase 4 | Unknown | Ruijin Hospital | 200 | 2012-09-01 | 2017-11-14 |
Immunoblastic Lymphadenopathy (3) · Enteropathy-Associated T-Cell Lymphoma (2) · Lymphoma, T-Cell (2) · Subcutaneous panniculitis-like T-cell lymphoma (2) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Recurrence (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphadenopathy (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Disease Attributes (1) · Lymphoma, T-Cell (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Cyclophosphamide (1) · Doxorubicin (1) · Etoposide (1) · Ifosfamide (1) · Methotrexate (1) · Prednisone (1) · Vincristine (1) · etoposide phosphate (1) · pirarubicin (1) · prednylidene (1) · tislelizumab (1)
BeiGene (1) · Ruijin Hospital (1) · Shandong Provincial Hospital (1)
China (3) · Canada (1) · France (1) · Italy (1) · Taiwan (1)
Xin Wang, PhD (1)
2017 (1)